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Background: Methotrexate (MTX) is an effective and safe drug in the treatment of juvenile idiopathic arthritis (JIA).
Despite its safety, MTX-related gastrointestinal adverse effects before and after MTX administration, termed MTX
intolerance, occur frequently, leading to non-compliance and potentially premature MTX termination. The aim of
this study was to construct a risk model to predict MTX intolerance.
Methods: In a prospective JIA cohort, clinical variables and single nucleotide polymorphisms were determined at
MTX start. The Methotrexate Intolerance Severity Score was employed to measure MTX intolerance in the first year
of treatment. MTX intolerance was most prevalent at 6 or 12 months after MTX start, which was defined as the
outcome for the prediction model. The model was developed in 152 patients using multivariable logistic regression
analysis and subsequently internally validated using bootstrapping.
Results: The prediction model included the following predictors: JIA category, antinuclear antibody, parent/patient
assessment of pain, Juvenile Arthritis Disease Activity Score-27, thrombocytes, alanine aminotransferase and creatinine.
The model classified 77.5% of patients correctly, and 66.7% of patients after internal validation by bootstrapping. The
lowest predicted risk of MTX intolerance was 18.9% and the highest predicted risk was 85.9%. The prediction model
was transformed into a risk score (range 0–17). At a cut-off of ≥6, sensitivity was 82.0%, specificity 56.1%, positive
predictive value was 58.7% and negative predictive value 80.4%.
Conclusions: This clinical prediction model showed moderate predictive power to detect MTX intolerance. To develop
into a clinically usable tool, it should be validated in an independent cohort and updated with new predictors. Such an
easy-to-use tool could then assist clinicians in identifying patients at risk to develop MTX intolerance, and in turn to
monitor them closely and intervene timely in order to prevent the development of MTX intolerance.
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Juvenile idiopathic arthritis (JIA) is the most common
childhood rheumatic disease [1,2]. In JIA, methotrexate
(MTX) is the cornerstone treatment, due to its efficacy
and safety. Serious adverse effects such as hepatotoxicity
and bone marrow suppression occur rarely [3]. In con-
trast, MTX-related gastrointestinal adverse effects,
such as nausea, abdominal pain and vomiting, occur
frequently [4-10]. Folic acid supplementation is an
accepted strategy to prevent and treat these adverse
effects [11-13]. Despite folic acid use, many JIA pa-
tients experience gastrointestinal adverse effects after
MTX intake [4-10]. JIA patients also experience antici-
patory adverse effects, occurring before MTX adminis-
tration (at the sight of MTX), and associative adverse
effects, occurring when thinking of MTX administra-
tion (its colour or smell) [4,5,14]. These adverse effects
are thought to be a result of classical conditioning to
the abovementioned physical symptoms experienced
after MTX intake [14]. Importantly, if physical symp-
toms are absent, conditioned responses cannot develop
[15]. Such a combination of symptoms, which we pre-
viously termed MTX intolerance, [14] is a significant
burden for JIA patients and their parents. Notably,
MTX intolerance occurs in up to half of JIA patients
on MTX, [14] and can negatively affect their quality of
life [6]. Moreover, over three-quarters of intolerant pa-
tients reluctantly used or even refused MTX, [14]
which, besides leading to non-compliance, could lead
to premature discontinuation of MTX, and even re-
placement by costly biologicals [5,16,17]. Such conse-
quences could be avoided, if the development of MTX
intolerance is prevented.
To prevent MTX intolerance, it is crucial to predict
which patients starting MTX will be at risk to develop it.
Thus, clinicians could be able to prevent MTX intolerance
in patients at risk by immediate treatment of emerging
physical symptoms, which otherwise could give rise to
conditioned responses. Treatment of physical symptoms
could include lowering the MTX dose, [4] or starting be-
havioural therapy [5] or anti-emetics [18]. Predicting
MTX intolerance would enable clinicians to apply such
treatment strategies only in those patients who are likely
to develop MTX intolerance.
Single nucleotide polymorphisms (SNPs) involved
in the MTX metabolic pathways, and clinical predic-
tors have been associated with MTX-related gastro-
intestinal adverse effects in rheumatoid arthritis (RA)
[19-28] and JIA, the latter of which were reviewed
recently [29]. However, to date no model has been
constructed to predict MTX intolerance in JIA. The
aim of this cohort study was to develop and intern-
ally validate such a prediction model, using clinical
and genetic predictors.Methods
Patients and study design
An investigator-initiated observational prospective study
on efficacy and adverse effects of MTX in patients
starting MTX (ISRCTN13524271) was performed at
the University Medical Centre Utrecht and Erasmus
University Medical Centre Rotterdam, The Netherlands,
between January 2008 and October 2012. It was approved
by the Ethics Committees of the participating centres and
the Central Committee on Research involving Human
Subjects, and was conducted according to good clinical
practice guidelines.
Patients aged 1–18 years, with a confirmed diagnosis
of JIA according to International League of Associations
for Rheumatology (ILAR) criteria, [30] who started
MTX, were included. Those who had stopped MTX for
at least three months, but re-started MTX due to a
relapse, were also included. At the time of MTX start,
their clinical data (Table 1) were documented in case
report forms and blood for the analysis of SNPs was
drawn.
All patients completed the previously developed and
validated MTX Intolerance Severity Score (MISS) at 3, 6
and 12 months after MTX start [14]. This questionnaire
consists of 12 questions, assessing abdominal pain, nau-
sea and vomiting after or before (anticipatory) MTX
intake and when thinking of MTX (associative). Further-
more, it assesses behavioural complaints associated with
MTX intake, such as crying, restlessness, irritability and
refusal to take the drug. The score ranges from 0 to 36
and those with a score of ≥6, including at least one
anticipatory, associative or behavioural symptom, were
defined as MTX intolerant [14].
Development of MTX intolerance over time and patient
selection
To define the outcome for the prediction model, the
development of MTX intolerance at 3, 6 and 12 months
after MTX start was assessed. For this analysis, of 175
patients starting MTX treatment, 8 patients were excluded
due to a diagnosis other than JIA (n = 4: Lyme disease, col-
itis, sarcoidosis, 22q11 deletion syndrome) and use of bio-
logicals at MTX start (n = 3: anakinra; n = 1: etanercept),
resulting in 167 eligible patients (Figure 1). Additionally,
25 patients who completed only one MISS during follow-
up were excluded, as their development of MTX intoler-
ance could not be determined. Therefore, the development
of MTX intolerance was assessed in 142 patients (Figure 1).
In the first year after MTX start, 59 (41.5%) patients were
intolerant (score ≥6 with at least one anticipatory, associa-
tive or behavioural complaint) (Table 2). At 3 months, 22
(15.7%) patients were intolerant. However, intolerance re-
solved in the majority of these (13 [59.1%]) at 6 months. At
6 months, the number of intolerant patients increased to
Table 1 Prevalence, univariable ORs (95%-CI) and p-values for potential predictors of MTX intolerance at MTX start
Cohort, n = 152
Variables Frequency n (%)a OR (95%-CI) p-value
Demographics
Female 92 (60.5) 1.34 (0.64-2.82) 0.432
Age at disease onset >8 years 80 (52.6) 0.68 (0.34-1.36) 0.271
Age at MTX start* >12 years 72 (47.4) 0.54 (0.27-1.07) 0.073
Disease duration at MTX start >0.5 years 103 (67.8) 0.79 (0.37-1.70) 0.535
JIA category*b
Oligoarticular (persistent/extended) 62 (40.8) Reference 0.094
Polyarticular (RF negative/positive) 64 (42.1) 1.91 (0.86-4.24)
Other (systemic/psoriatic/enthesitis) 26 (17.1) 0.78 (0.27-2.31)
Disease characteristics
ANA*b,c Positive 84 (55.3) 1.98 (0.97-4.07) 0.057
RFc Positive 16 (10.5) 1.52 (0.62-3.72) 0.352
HLA-B27c Positive 11 (7.2) 0.78 (0.29-2.12) 0.510
Uveitis Present 21 (13.8) 1.44 (0.55-3.78) 0.455
Disease activity
CHAQ disability scorec ≤0.250 36 (23.7) Reference 0.395
0.250-1.875 88 (57.9) 0.61 (0.24-1.55)
>1.875 15 (9.9) 0.72 (0.18-2.80)
Parent/patient assessment of pain*b,c ≤3 cm 58 (38.2) Reference 0.086
3-6 cm 36 (23.7) 2.19 (0.84-5.67)
>6 cm 42 (27.6) 0.78 (0.30-2.02)
Parent/patient global assessmentc >2.5 cm 90 (59.2) 0.79 (0.36-1.72) 0.494
Active joints* >2 92 (60.5) 2.00 (0.91-4.41) 0.070
Limited joints* >1 108 (71.1) 2.02 (0.92-4.46) 0.072
PGAd ≤2 cm 50 (32.9) Reference 0.496
2-5 cm 86 (56.6) 1.35 (0.53-3.47)
>5 cm 16 (10.5) 0.87 (0.21-3.60)
ESRc >15 mm/hr 74 (48.7) 1.46 (0.66-3.25) 0.341
CRPc >10 mg/L 49 (32.2) 0.83 (0.40-1.74) 0.544
JADAS-27*b,c ≤5 16 (10.5) Reference 0.048
5-15 59 (38.8) 0.40 (0.11-1.40)
>15 52 (34.2) 0.93 (0.25-3.44)
Biochemical variablesc
Haemoglobin >7.5 mmol/L 78 (51.3) 1.18 (0.60-2.32) 0.620
Leucocytes >7 × 109/L 96 (63.2) 1.21 (0.59-2.47) 0.606
Thrombocytes*b >350 × 109/L 74 (48.7) 1.61 (0.82-3.16) 0.161
AST >17 IU/L 96 (63.2) 1.08 (0.50-2.36) 0.635
ALT*b >12 IU/L 101 (66.4) 0.41 (0.19-0.88) 0.019
Creatinine*b >50 μmol/L 56 (36.8) 0.51 (0.24-1.08) 0.069
Medication
MTX dose, median (IQR) mg/m2/week 9.9 (9.0-11.2) NA
MTX route oral 148 (97.4) NA
MTX restarted 31 (20.4) 1.22 (0.48-3.11) 0.554
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Table 1 Prevalence, univariable ORs (95%-CI) and p-values for potential predictors of MTX intolerance at MTX start
(Continued)
Folic acid 150 (98.7) NA
Anti-emetics 5 (3.3) NA
NSAID 120 (78.9) 0.93 (0.38-2.28) 0.655
Single nucleotide polymorphismsc
MTHFR rs1801133 C > T TT 15 (9.9) 0.60 (0.21-1.69) 0.322
MTHFR rs1801131 A > C CC/AC 79 (52.0) 1.65 (0.76-3.62) 0.201
MTRR rs1801394 A > G* GG/AG 117 (77.0) 0.53 (0.24-1.20) 0.123
RFC/SLC19A1 rs1051266 C > T* TT 17 (11.2) 1.77 (0.74-4.25) 0.194
ITPA rs1127354 C > A AA/CA 15 (9.9) 0.62 (0.22-1.74) 0.350
AMPD1 rs17602729 G > A AA/GA 41 (27.0) 1.46 (0.70-3.05) 0.304
ATIC rs2372536 C > G GG/CG 93 (61.2) 0.84 (0.39-1.83) 0.614
ADA22 rs73598374 C > T TT/CT 13 (8.6) NA
ADORA2A rs5751876 C > T TT 28 (18.4) 1.54 (0.65-3.64) 0.319
MDR-1/ABCB1 rs 128503 G > A* AA 32 (21.1) 1.73 (0.75-3.98) 0.190
MDR-1/ABCB1 rs1045642 G > A AA 44 (28.9) 1.40 (0.65-3.01) 0.376
MDR-1/ABCB1 rs2032582 C > A/T AA/TT 24 (15.8) 1.51 (0.63-3.64) 0.344
MRP-1/ABCC1 rs35592 T > C CC/TC 52 (34.2) 0.79 (0.39-1.57) 0.494
MRP-1/ABCC1 rs3784862 A > G GG/AG 73 (48.0) 0.97 (0.50-1.91) 0.824
MRP-2/ABCC2 rs4148396 C > T TT 18 (11.8) 1.57 (0.60-4.08) 0.349
MRP-2/ABCC2 rs717620 C > T TT/CT 44 (28.9) 0.82 (0.37-1.82) 0.626
MRP-3/ABCC3 rs4793665 T > C CC/TC 92 (60.5) 0.73 (0.36-1.49) 0.381
MRP-3/ABCC3 rs3785911 A > C* CC/AC 78 (51.3) 1.67 (0.84-3.32) 0.136
MRP-4/ABCC4 rs868853 T > C CC/TC 22 (14.5) 0.88 (0.35-2.18) 0.734
MRP-4/ABCC4 rs2274407 C > A AA/CA 20 (13.2) 1.33 (0.48-3.73) 0.514
MRP-5/ABCC5 rs2139560 G > A AA/GA 92 (60.5) 1.31 (0.64-2.68) 0.450
BCRP/ABCG2 rs13120400 T > C CC/TC 63 (41.4) 0.77 (0.38-1.59) 0.470
BCRP/ABCG2 rs2231142 G > T TT/GT 30 (19.7) 0.96 (0.42-2.20) 0.744
FPGS rs4451422 A > C CC/AC 102 (67.1) 1.37 (0.63-2.94) 0.417
GGH rs10106587 A > C CC/AC 73 (48.0) 1.20 (0.59-2.46) 0.508
GGH rs3758149 G > A AA/GA 77 (50.7) 1.20 (0.57-2.55) 0.602
PCFT/SLC46A1 rs2239907 C > T TT/CT 104 (68.4) 1.49 (0.69-3.23) 0.306
Abbreviations: ALT, alanine aminotransferase; ANA, antinuclear antibody; AST, asparagine aminotransferase; CHAQ, childhood health assessment questionnaire; CI,
confidence interval; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; HLA, human leucocyte antigen; IQR, interquartile range; IU, international units;
JADAS, juvenile arthritis disease activity score; JIA, juvenile idiopathic arthritis; MICE, multivariate imputation by chained equations; MTX, methotrexate; NSAID,
non-steroidal anti-inflammatory drug; OR, odds ratio; PGA, physician global assessment; RF, rheumatoid factor.
*Variables associated with the outcome at p < 0.20 in the univariable logistic regression analysis. Variables with observed frequencies of <5 in the cross-tabulation
with the outcome were excluded from the univariable logistic analysis: MTX route, use of folic acid, use of anti-emetics and ADA22 rs73598374.
aFrequencies are based on observed data, not imputed data.
bJIA category, ANA, parent/patient assessment of pain, JADAS-27, thrombocytes, ALT and creatinine were included in the multivariable logistic regression analysis.
cMICE was used to impute missing values in the following variables (percentage of missing values): HLA-B27 (60.5), RF (19.1), JADAS-27 (16.4), CRP (15.8),
parent/patient global assessment (11.8), RFC/SLC19A1 rs1051266 (11.8), creatinine (11.2), parent/patient assessment of pain (10.5), CHAQ disability score (8.6),
MDR-1/ABCB1 rs2032582 (8.6), ALT (7.9), AST (7.2), ESR (5.3), GGH rs3758149 (4.6), MRP-2/ABCC2 rs717620 (3.9), MRP-4/ABCC4 rs868853 (3.9), MRP-5/ABCC5
rs2139560 (3.9), GGH rs10106587 (3.9), MTHFR rs1801131 (3.3), ATIC rs2372536 (3.3), ADORA2A rs5751876 (3.3), MRP-1/ABCC1 rs3784862 (3.3), MRP-2/ABCC2
rs4148396 (3.3), MRP-3/ABCC3 rs4793665 (3.3), BCRP/ABCG2 rs13120400 (3.3), PCFT/SLC46A1 rs2239907 (3.3), MTHFR rs1801133 (2.6), MTRR rs1801394 (2.6), ITPA
rs1127354 (2.6), AMPD1 rs17602729 (2.6), ADA22 rs73598374 (2.6), MDR-1/ABCB1 rs1128503 and rs1045642 (2.6), MRP-1/ABCC1 rs35592 (2.6), MRP-3/ABCC3
rs3785911 (2.6), MRP-4/ABCC4 rs2274407 (2.6), BCRP/ABCG2 rs2231142 (2.6), FPGS rs4451422 (2.6), thrombocytes (2.0), ANA (2.0), hemoglobin (1.3), leucocytes (1.3).
dPGA was determined retrospectively by an experienced physician (SJV) in 20 visits (13.2%).
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12 months, 14 (42.4%) of those intolerant at 6 months
stayed intolerant, whereas 8 had less than 6 points on theMISS and 11 did not complete it. The total number of in-
tolerant patients at 12 months was 30 (23.3%), of whom
13 (43.3%) were newly intolerant (Table 2).
Figure 1 Flowchart. Abbreviations: MISS, Methotrexate Intolerance Severity Score; MTX, methotrexate.
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MTX intolerance did so at 6 or 12 months after MTX
start. Consequently, the outcome for the prediction model
was defined as MTX intolerance at 6 or 12 months after
MTX start.
For the construction of the prediction model, patients
with a completed MISS at 6 or 12 months were re-
selected from the eligible cohort of 167 patients, result-
ing in 152 included patients (Figure 1).
Potential clinical and genetic predictors
Potential clinical predictors (demographics, JIA category,
disease characteristics, disease activity and biochemical
measurements) were identified at baseline (Table 1).
Potential genetic predictors were SNPs involved in the
MTX metabolic pathways, with a high polymorphic
allele frequency and documented functional effects
[31]. SNPs were determined in the following genes:
methylenetetrahydrofolate reductase (MTHFR), reduced
folate carrier (RFC), methionine synthase reductase
(MTRR), inosine triphosphatase (ITPA), adenosine
monophosphate deaminase (AMPD), aminoimidazole-
4-carboxamide ribonucleotide transformylase (ATIC),
adenosine-deaminase (ADA), adenosine A2A receptor
(ADORA2A), multidrug resistance (MDR) 1, multidrug
resistance protein (MRP) 1–5, breast cancer resistance
protein (BCRP), folylpolyglutamate synthase (FPGS),
gamma glutamyl hydrolase (GGH) and proton-coupled
folate transporter (PCFT) (Table 1).Table 2 MTX intolerance development
Time point N Intolerance, n(%)a
3 months 140b 22 (15.7)
6 months 137b 33 (24.1)
12 months 129b 30 (23.3)
First treatment year 142 59 (41.5)
6 or 12 monthsd 152c 51 (33.6)
Abbreviations: MTX, methotrexate; n, number of patients.
aFrequencies are based on observed data;
bPatients still on MTX; cCohort for
prediction model construction; dOutcome was imputed in 21.7% of cases.Statistical analysis
Prediction model construction
The prediction model was constructed in several steps.
First, missing values were imputed using multivariate
imputation by chained equations (MICE) [32]. This was
done to ensure that all collected data could be used for
the development of the model. Second, to facilitate im-
plementation of the model in daily clinical practice,
continuous variables were dichotomised or categorised,
according to patterns in the data or the risk gradients
across percentiles, and the cut-off points with the lowest
p-value on the log-likelihood ratio test (i.e. those yield-
ing the optimal association) were chosen [33]. Third, all
variables were entered in a univariable logistic regres-
sion analysis. The results are presented as regression co-
efficients (β) and odds ratios (OR) with 95% confidence
intervals (95% CI). The regression coefficients are an
indication of the direction and the magnitude of the
effect of the individual predictors, whereas the ORs with
95% CI indicate the significance of the association.
Variables with a p-value <0.20 on the log-likelihood
ratio test in the univariable analysis were eligible for in-
clusion in the multivariable logistic regression analysis.
The maximum number of included variables equalled
the square root of the number of cases (MTX intolerant
patients) in the cohort. If more variables were eligible
than the allowed maximum, or if variables correlated
(Spearman’s |rho| >0.40), those with the lowest p-value
on the log-likelihood ratio test were included in the
multivariable analysis. In addition, presence of effect
modification by the predictors in the model was assessed.
Effect modification is the situation in which the effect of
one predictor on the outcome is modified by the value of
another factor. For example, the effect of a predictor may
differ between boys and girls. Statistically, this is tested by
adding interaction terms to the model, allowing the re-
gression coefficients to take different values for different
categories of patients.
Predictive power of the model was assessed with the
C-statistic, which reflects the percentage of patients
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the data well, the Hosmer-Lemeshow test was employed.
Multicollinearity was tested with variance inflation fac-
tors (VIF).
Prediction model validation and risk score computation
All prediction models need to be validated. Since no in-
dependent cohort was available, the model was internally
validated using an established statistical technique, called
bootstrap [34-36]. In short, 200 bootstrap cohorts (of
equal size as the original dataset, n = 152) were randomly
drawn, with replacement, from the cases in the original
dataset. Next, to each bootstrap cohort, bootstrap multi-
variable models were fitted (200 in total) using exactly the
same methods as described above for the original model,
and the corresponding C-statistics (Cboot) were deter-
mined. Then, the probability of MTX intolerance of the
patients in the original dataset was calculated using each
of these multivariable models, resulting in another set of
C-statistics (Cboot-original) reflecting the percentage of pa-
tients predicted correctly according to each of these
models. The difference between Cboot-original values and
Cboot values is an estimate of the so-called optimism value
(i.e. how much the original model fitted to the original
dataset was optimistic compared to the “real” performance
of the model in the population). Therefore, in order to ob-
tain the final adjusted C-statistic, indicating the “real” per-
formance of the model in the population, [36] two
additional steps need to be performed: a) Subtraction of
Cboot-original values from Cboot values and averaging them
in order to obtain the optimism value; b) Subtraction of
this optimism value from Coriginal (the C-statistic of the
original model, developed in the original dataset), thus
obtaining the final adjusted C-statistic. Furthermore, to
correct for overfitting, the regression coefficients were re-
duced with a shrinkage factor, calculated from the boot-
strap re-sampling.
All the above mentioned procedures were performed
twice. Firstly, only the routinely available clinical vari-
ables were considered as potential predictors. Secondly,
SNPs were also considered as potential predictors in
order to determine whether they contributed to the pre-
diction of MTX intolerance.
To compute a risk score of becoming MTX intolerant,
the shrunken regression coefficients were multiplied and
rounded off to obtain simple scores that sum up to a
total risk score. Sensitivity, specificity, positive predictive
value (PPV), negative predictive value (NPV) and accur-
acy of various cut-off points were calculated.
Statistical analyses were carried out with R statistics
version 2.15.0 (R Foundation for Statistical Computing,
Vienna, Austria), using the packages Hmisc (by Frank E
Harrell Jr with contributions from many other users,
version 3.9-3, 2012) and mice [32].Results
Baseline characteristics of the prediction model cohort
The prediction model was constructed in 152 patients.
According to the outcome as defined above, 51 (33.6%)
patients were MTX intolerant (Table 2). Intolerant and
tolerant patients did not differ regarding the proportion
of MTX re-starters, MTX dose, route of administration,
concomitant medication use or disease activity (Juvenile
Arthritis Disease Activity score [JADAS-27]) at 6 and
12 months after MTX start (data not shown).
Nineteen (12.5%) patients discontinued MTX treatment
during the follow-up, because of MTX intolerance (n = 8),
disease remission (n = 3), insufficient effect (n = 2), MTX
toxicity (increased liver enzymes: n = 1) or other reasons
(n = 5). Patients also switched the route of administration
due to gastrointestinal complaints (either from oral to
subcutaneous or vice versa): 8 patients after 3 months, 6
patients after 6 months and 1 patient after 12 months.
Baseline characteristics are depicted in Table 1. Thirty-
one patients (20.4%) had re-started MTX treatment due
to a relapse after at least three months discontinuation.
The majority of patients had either oligoarticular or poly-
articular JIA (82.9%), with high disease activity (median
JADAS-27 of 12.7 [interquartile range 7.6-18.2]). Median
MTX dose was 9.9 mg/m2/week, administered mostly as
oral MTX (97.4%) with concomitant use of folic acid
(98.7%).
Clinical prediction model
First, a model was constructed, containing clinical vari-
ables only, excluding the SNPs. Ten clinical variables
were associated in the univariable analysis with MTX in-
tolerance (p < 0.20; Table 1). The maximum number of
variables allowed in the multivariable analysis was seven.
Those with the lowest p-value were selected for the clin-
ical prediction model, namely JIA category, JADAS-27,
parent/patient assessment of pain, antinuclear antibody
(ANA), alanine aminotransferase (ALT), thrombocytes
and creatinine, and an interaction term between creatin-
ine and JIA category was added. The C-statistic of the
clinical prediction model was 77.5% (Table 3). The
model fit the data well, as shown by a non-significant
Hosmer-Lemeshow test (p = 0.705). There was no multi-
collinearity (data not shown).
Clinical-genetic prediction model
Next, SNPs were considered as potential predictors in
order to determine their contribution to MTX intolerance
prediction. Four SNPs in the MTRR, RFC, MDR-1 and
MRP-3 genes had univariable p-values of <0.20, however
these p-values (range: 0.123-0.194) were generally higher
than those of the clinical model variables (range: 0.048-
0.161) (Table 1). Hence, since seven variables with the
smallest p-values were selected for multivariable analysis,
Table 3 Prediction model and scores for MTX intolerance
Predictors OR (95%-CI) p-value βa Scoreb
JIA category
Oligoarticular (persistent/extended) Reference 0
Polyarticular (RF negative/positive) 4.99 (1.36-18.34) 0.016 0.914 5
Other (systemic/psoriatic/enthesitis) 0.93 (0.16-5.49) 0.935 −0.042 0
ANA Positive 1.98 (0.83-4.68) 0.122 0.387 2
Parent/patient assessment of pain ≤3 cm Reference 0
3-6 cm 2.06 (0.72-5.89) 0.175 0.412 2
>6 cm 0.60 (0.17-2.07) 0.421 −0.288 −1
JADAS-27 ≤5 Reference 0
5-15 0.35 (0.08-1.56) 0.168 −0.599 −3
>15 0.77 (0.14-4.32) 0.766 −0.150 −1
Thrombocytes >350 × 109/L 1.27 (0.49-3.27) 0.621 0.136 1
ALT >12 IU/L 0.39 (0.16-0.96) 0.040 −0.534 −3
Creatinine >50 μmol/L 1.37 (0.33-5.67) 0.665 0.179 1
Interaction term creatinine: JIA category
>50 μmol/L & polyarticular arthritis 0.17 (0.02-1.35) 0.093 −1.022 −5
>50 μmol/L & other JIA category 0.82 (0.07-9.74) 0.878 −0.110 −1
Constant −0.039 7
C-statistic 77.5%
C-statistic (optimism-corrected by bootstrap) 66.7%
Hosmer-Lemeshow test (p-value) 0.705
Abbreviations: ALT, alanine aminotransferase; ANA, anti-nuclear antibody; CI, confidence interval; JADAS, juvenile arthritis disease activity score; JIA, juvenile
idiopathic arthritis; MTX, methotrexate; OR, odds ratio; RF, rheumatoid factor.
aThese are shrunk coefficients (by factor 0.5688) to correct for overfitting.
bShrunk coefficients were multiplied by 5 and rounded off to the nearest integer. The constant was adjusted to obtain the minimum score of 0.
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ables (those from the abovementioned clinical model, ex-
cluding thrombocytes), were included in the model. The
model’s C-statistic was 77.7%.
Prediction model validation
Both the clinical and the clinical-genetic prediction model
were internally validated using bootstrapping. Upon in-
ternal validation, the corrected C-statistic of the clinical
model was 66.7%, whereas the corrected C-statistic of the
clinical-genetic model was 64.6%.
Since the clinical-genetic model did not perform better
than the model with clinical variables, the latter was
given preference as clinical variables are readily available
at MTX start, making it easier to apply the model in
clinical practice.
Risk score
To enable health care professionals to use the model
easily, the shrunken regression coefficients of the clinical
model’s predictors, transformed into simple scores, were
used to compute an individual risk score for being MTX
intolerant. This score ranged from 0 to 17 points, with ahigher score reflecting a higher probability of MTX in-
tolerance (Table 3). The lowest predicted risk of being
MTX intolerant was 18.9%, if the following predictors
were present: oligoarticular JIA, negative ANA, parent/
patient assessment of pain >6 cm, JADAS-27 of 5–15
points, thrombocytes ≤350 × 109/L, ALT >12 IU/L and
creatinine ≤50 μmol/L. The combination of these predic-
tors resulted in a score of 0 [7 (the constant) + 0 + 0 +
(−1) + (−3) + 0 + (−3) + 0] (Table 3). On the other hand,
the highest predicted risk of being MTX intolerant was
85.9%, if the following predictors were present: polyarticu-
lar JIA, positive ANA, parent/patient assessment of pain
of 3–6 cm, JADAS-27 ≤ 5 points, thrombocytes >350 ×
109/L, ALT ≤12 IU/L and creatinine ≤50 μmol/L. The
combination of these predictors resulted in a score of 17
[7 + 5 + 2 + 2 + 0 + 1 + 0 + 0].
Within the 0–17 range, the diagnostic accuracy of dif-
ferent cut-off scores for predicting the risk of being
MTX intolerant was evaluated by computing the corre-
sponding sensitivity, specificity, PPV, NPV, and accuracy
(Table 4). Our goal was to correctly identify as many
future MTX intolerant patients as possible (high sensi-
tivity), while attempting to avoid misidentification of
Table 4 Diagnostic parameters of the risk score for various cut-off scores
Cut-off Sensitivity (%) Specificity (%) PPV (%) NPV (%) Accuracy (%)
≥4 93.4 29.9 50.3 85.7 57.3
≥5 87.8 46.1 55.3 83.3 64.1
≥6 82.0 56.1 58.7 80.4 67.3
≥7 69.2 69.9 63.6 74.9 69.6
≥8 58.7 80.3 69.4 71.9 71.0
≥9 46.0 86.8 72.6 67.9 69.2
Abbreviations: NPV, negative predictive value; PPV, positive predictive value.
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city). This was reached at the cut-off score ≥6, where
82% of intolerant patients and 56.1% of tolerant patients
were identified correctly.
Discussion
We developed and internally validated a prediction
model for MTX intolerance at 6 or 12 months after
MTX start in a large JIA cohort, consisting of routine
clinical variables: JIA category, JADAS-27, parent/patient
assessment of pain, ANA, ALT, thrombocytes, creatinine
and an interaction term between creatinine and JIA cat-
egory. The model classified 77.5% of patients correctly,
and 66.7% after internal validation. It should be validated
in an independent cohort and updated with other
predictors.
In our model, patients who had more pain (>6 cm),
higher baseline disease activity assessed with JADAS-27
and higher ALT, had a lower risk to become MTX in-
tolerant. On the other hand, patients with positive ANA,
who had less pain (3–6 cm), higher thrombocyte levels
and higher creatinine, had an increased risk of MTX
intolerance. Creatinine level and age were correlated,
so creatinin can be regarded as a surrogate marker
for age (median age was 7.5 years [patients with creatinine
≤50 μmol/L] versus 13.7 years [creatinine >50 μmol/L]).
The relationship between JIA category, creatinine (age)
and MTX intolerance was complex: In younger patients,
polyarticular JIA was a strong predictor for intolerance
(score 5, Table 3), whereas in older patients this effect dis-
appeared (score 5 for polyarticular JIA and −5 for the
interaction term between older patients (higher creatinine)
and polyarticular JIA).
To predict which patients are prone to develop MTX
intolerance, our risk score could be readily used by clini-
cians, since it is based on clinical variables, which are
routinely determined and available for all JIA patients
before MTX start. At the cut-off score of ≥6, as many as
82% of intolerant patients were classified correctly (high
sensitivity), while maintaining correct classification of
56.1% of tolerant patients (modest specificity). Table 4
provides the sensitivity and specificity of other potential
cut off points.Identification of patients at risk increases patients’ and
clinicians’ awareness of MTX intolerance. In patients at
risk, clinicians should frequently (i.e. every 4 weeks)
monitor MTX-related gastrointestinal adverse effects,
using the MISS, from the very start of MTX treatment.
This would enable clinicians to treat the emerging phys-
ical symptoms early, for example by lowering MTX dose,
[4] adding anti-emetics [18] or applying behavioural
therapy, [5] thus preventing the development of a clas-
sical conditioning response [15] and hence MTX intoler-
ance. The effect of these timely interventions on the
development of MTX intolerance should be determined
in a clinical trial.
The outcome of our prediction model was defined as
MTX intolerance at 6 or 12 months after MTX start,
since the majority of patients developing MTX intoler-
ance did so at these time-points. The later onset of
MTX intolerance is consistent with the notion that the
development of MTX intolerance is governed by a clas-
sical conditioning response, which worsens over time
[5,14]. Moreover, in our previous cross-sectional study
in patients with longer MTX use (interquartile range:
0.6-3.6 years), we demonstrated higher prevalence of
MTX intolerance (50.5-67.5%) compared to the preva-
lence of 34.1% in the present longitudinal study during
the first year of MTX treatment [14]. This also supports
the notion that MTX intolerance takes time to develop
and that longer MTX use may increase the risk of MTX
intolerance. To determine whether the risk of MTX
intolerance indeed increases with longer MTX use,
development of MTX intolerance should be monitored
beyond one year of MTX use. Nevertheless, MTX in-
tolerance ensued in 15.8% of patients already after
3 months of MTX use. Interestingly, patients who had
restarted MTX had a higher risk of becoming intolerant
after 3 months than those newly starting MTX (36% ver-
sus 12.7%, p = 0.015).
To our knowledge, no previous studies have developed
a similar model and a corresponding risk score to pre-
dict the occurrence of MTX-induced gastrointestinal ad-
verse effects in JIA. In a recently published paper,
predictors for MTX adverse events in JIA patients, in-
cluding the predictors in the current model, were
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dated, and validation of these lacked [29].
Our study did not identify genotypes as predictors for
intolerance. In contrast, in RA, two studies identified
combinations of risk genotypes to predict adverse effects
in general and gastrointestinal adverse effects in particu-
lar [20,26]. In our study, only 4 of 27 SNPs were moder-
ately associated with MTX intolerance and only one
SNP could be included in the clinical-genetic model,
which had comparable predictive power as the clinical
model. Previously, in RA and JIA, significant associa-
tions (p < 0.05) were reported between SNPs in the
MTHFR, ATIC, ADORA, MRP2/ABCC2 and GGH genes
and gastrointestinal adverse effects [19-22,24-28,37,38].
SNPs in these genes were not associated with MTX in-
tolerance in our study, which could be due to disparities
in patient groups (RA versus JIA), cohorts (cross-sec-
tional versus longitudinal), and the definition of MTX-
induced gastrointestinal complaints (after MTX versus
before and after MTX use). These results taken together
with our current study show that it is still difficult to
predict reliably the risk of developing MTX adverse
events in general and MTX intolerance in particular.
The strengths of our study were that MTX intolerance
was assessed using a validated questionnaire. In addition,
the model was constructed and internally validated in a
large prospective JIA cohort. Internal validation using
bootstrapping is an established method to estimate the
performance of a prediction model in the population,
comparable to external validation in an independent co-
hort [34-36].
Conclusions
In conclusion, we developed and internally validated a
clinical prediction model for MTX intolerance in a large
JIA cohort. It is an easy-to-use tool to identify patients
at risk of developing MTX intolerance, and in turn to
monitor them closely and intervene timely, in order to
prevent MTX intolerance and its negative impact on pa-
tients’ daily lives, compliance and continuation of an ef-
fective treatment. In its current composition, the model
performs moderately well and should be validated in an
independent cohort and updated with new predictor var-
iables before it can be broadly used in clinical practice.
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